BioSyent Inc. (RX.V) Research

BioSyent Inc. is a specialized pharmaceutical enterprise operating both within Canada and internationally. The company is actively involved in identifying, obtaining, developing, and commercializing a diverse portfolio of pharmaceutical and health-related products. Among its offerings are iron supplements such as FeraMAX 150, FeraMAX Powder (a water-soluble oral iron solution promoting red blood cell formation), and FeraMAX Pd Therapeutic 150, all designed to prevent and manage iron deficiency anemia. BioSyent also provides Cathejell, utilized for surface anesthesia and lubrication during various medical procedures including cystoscopy, catheterization, endoscopy, and tracheal intubation, as well as for symptomatic relief of pain associated with cystitis and urethritis. Other key products include RepaGyn, a vaginal suppository aimed at healing vaginal mucosa and alleviating dryness caused by factors like menopause, stress, and chemotherapy, and Proktis-M, a rectal suppository supporting the healing of the anal and rectal areas. Furthermore, its lineup features Combogesic for reducing moderate acute pain and fever in adults, Protect-It, a non-chemical, food-safe grain insecticide used to prevent insect infestations in stored grains, and Tibella, a hormone replacement therapy addressing vasomotor symptoms stemming from estrogen deficiency. The company distributes its products through wholesalers and retail pharmacy chains. Headquartered in Mississauga, Canada, BioSyent Inc. was incorporated in 2006, having previously operated as Hedley Technologies Inc. before rebranding in June 2006 to emphasize its strategic focus on the pharmaceutical sector.

Open BioSyent Inc. (RX.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.